CCND1 and non-small cell lung carcinoma: As shown in the Fig. 5E, F of 7 types of NSCLC cells, with increasing dosage of bortezomib, the expressions of cell cycle blocking protein p16, p21 and p27 were significantly increased, and the expressions of CDK4, CDK6, CCND1 and CCNE1 involved in G1 phase were significantly decreased.